Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the ...

Breyanzi (lisocabtagene maraleucel) is a type of treatment called a chimeric antigen receptor T-cell therapy (CAR T-cell) that uses your body's own immune system to treat your cancer. Breyanzi was ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

Retail investor chatter around Bristol Myers Squibb intensified on Monday following the release of new clinical data, which revealed deep and durable results from Breyanzi in treating patients with ...

Bristol Myers Squibb today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi ® in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

Breyanzi and its Previous Approvals. Breyanzi is a CD19-directed CAR T cell therapy that includes a 4-1BB costimulatory domain, which helps enhance the expansion and persistence of the CAR T cells in ...

Bristol Myers Squibb has announced that the FDA has given approval to label updates for Breyanzi and Abecma to treat multiple myeloma.

Breyanzi is also approved in Japan, the European Union (EU), Switzerland, the United Kingdom and Canada for the treatment of relapsed or refractory LBCL after at least one prior line of therapy; ...